Hypoxia-inducible Factor 1–dependent Induction of Intestinal Trefoil Factor Protects Barrier Function during Hypoxia

By Glenn T. Furuta,*§ Jerrold R. Turner,§ Cormac T. Taylor,* Robert M. Hershberg,¶ Katrina Comerford,* Sailaja Narravula,* Daniel K. Podolsky,‡ and Sean P. Colgan*

From the *Center for Experimental Therapeutics and Reperfusion Injury, the §Division of Gastroenterology, Brigham and Women’s Hospital, the ¶Combined Program for Pediatric Gastroenterology and Nutrition, Children’s Hospital, and the Center for Study of Inflammatory Bowel Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02115; and the *Department of Pathology, Wayne State University, Detroit, Michigan 48201

Abstract
Mucosal organs such as the intestine are supported by a rich and complex underlying vasculature. For this reason, the intestine, and particularly barrier-protective epithelial cells, are susceptible to damage related to diminished blood flow and concomitant tissue hypoxia. We sought to identify compensatory mechanisms that protect epithelial barrier during episodes of intestinal hypoxia. Initial studies examining T84 colonic epithelial cells revealed that barrier function is uniquely resistant to changes elicited by hypoxia. A search for intestinal-specific, barrier-protective factors revealed that the human intestinal trefoil factor (ITF) gene promoter bears a previously unappreciated binding site for hypoxia-inducible factor (HIF)-1. Hypoxia resulted in parallel induction of ITF mRNA and protein. Electrophoretic mobility shift assay analysis using ITF-specific, HIF-1 consensus motifs resulted in a hypoxia-inducible DNA binding activity, and loading cells with antisense oligonucleotides directed against the α chain of HIF-1 resulted in a loss of ITF hypoxia inducibility. Moreover, addition of anti-ITF antibody resulted in a loss of barrier function in epithelial cells exposed to hypoxia, and the addition of recombinant human ITF to vascular endothelial cells partially protected endothelial cells from hypoxia-elicited barrier disruption. Extensions of these studies in vivo revealed prominent hypoxia-elicited increases in intestinal permeability in ITF null mice. HIF-1–dependent induction of ITF may provide an adaptive link for maintenance of barrier function during hypoxia.

Key words: epithelium • gastrointestinal disease • transcription factor • intestinal permeability • endothelium

Introduction
Epithelial cells are anatomically positioned to provide a barrier to antigenic flux and luminal bacteria (1). Mucosal organs, such as the intestine, rely on an extensive underlying vasculature, and therefore are primary sites for conditions of diminished blood flow and resultant tissue hypoxia (2). Under such conditions, maintenance of barrier function depends on structures within the intercellular tight junction at the boundary of the apical and basolateral membrane domain. At present, it is not known if protective mechanisms exist to support functional epithelial barrier properties during episodes of diminished blood flow and resultant hypoxia.

Both adaptive (e.g., erythropoietin [EPO],1 glycolytic enzymes) and proinflammatory (e.g., TNF-α, IL-8) responses have been attributed to conditions of diminished tissue oxygen delivery (hypoxia), and it is now clear that responses to hypoxia include transcriptionally regulated gene

1Abbreviations used in this paper: EMSA, electrophoretic mobility shift assay; EPO, erythropoietin; HIF, hypoxia-inducible factor; HRE, hypoxic response element; ITF, intestinal trefoil factor; MDCK, Madin-Darby canine kidney; MVEC, microvascular endothelial cell; RT, reverse transcription.
expression (2, 3). One such transcriptional pathway relies on the activation of hypoxia-inducible factor (HIF)-1, a member of the rapidly growing per-ARNT-sim family of basic helix-loop-helix (bHLH) transcription factors (4–6). Functional HIF-1 exists as an αβ heterodimer, the activation of which is dependent on stabilization of an O2-dependent degradation pathway (7). Binding of HIF-1 to DNA consensus domains (5′-RCGTG-3′) results in the transcriptional induction of HIF-1–bearing gene promoters (3). HIF-1 is widely expressed and recent studies indicate that consensus HIF-1–binding sequences exist in a number of genes (3). Here we demonstrate that hypoxia induces the epithelial-specific, barrier-protective protein intestinal trefoil factor (ITF) through an HIF-1–dependent mechanism.

Materials and Methods

Growth and Maintenance of Cell Lines. T84 cells and a subclone of Caco-2 B Be cells with high epithelial resistance were grown as monolayers on polycarbonate permeable supports as described previously (8, 9). The KB cell line is a human oral epithelial cell line derived from native human mucosa (10). Human microvascular endothelial cells (MVECs) are primary culture endothelial cells (Cascade Biologics, Inc.) derived from the human dermis and were cultured as described previously (11). Madin-Darby canine kidney (MDCK) cells were cultured and passaged as described previously (12). Confluent cells were exposed to hypoxia in a humidified hypoxic cell chamber (Coy Laboratory Products, Inc.) as described previously (13). Standard hypoxic conditions (based on previous work; references 13–15) were PO2 = 20 Torr, PCO2 = 35 Torr, with the balance made up of nitrogen and water vapor. Normoxic controls were cells exposed to the same experimental protocols under conditions of atmospheric oxygen concentrations (PO2 = 147 Torr and PCO2 = 35 Torr within a tissue culture incubator). Paracellullar permeability was assessed as described previously (11) using FITC-labeled dextran (40 kD).

Transcriptional Analysis. The transcriptional profile of epithelial cells exposed to ambient hypoxia was assessed in RNA derived from control or hypoxic epithelia (T84 cells at 6- or 18-h hypoxia) using quantitative gene chip expression arrays (Affymetrix, Inc.; reference 16). Reverse transcription (RT)–PCR analysis of mRNA levels was performed using DNase-treated total RNA as described previously (14) using primers specific for human ITF (17) resulting in a 108-bp fragment or β-actin (14) resulting in a 661-bp fragment. In subsets of experiments, the transcription inhibitor actinomycin D (10 ng/ml final concentration) was added, ITF mRNA was quantified by RT-PCR as described above (see Transcriptional Analysis). HIF-1α Transfection. Stable cell lines overexpressing HIF-1α (plasmid provided by H.F. Bunn, Harvard Medical School; reference 7) were generated in the high resistance Caco-2 B Be cell line as described previously (8). Primary screening for HIF-1 expression was by RT-PCR analysis. Clones with the highest expression underwent secondary screens based on electrophysiological characteristics (high resistance monolayers) and Western blot analysis of HIF-1α.

Intestinal Permeability In Vivo. The generation of ITF null mice has been described previously (21). Intestinal permeability was examined in 6–10-wk-old wild-type Bl1/29 (Taconic, Inc.) or ITF null mice using an FITC-labeled dextran method as described previously (22). Mice were gavaged with 60 mg/100 g body weight of FITC–dextran (4,000 kD at 80 mg/ml; Sigma-Aldrich) and exposed to ambient hypoxia (8% O2, 92% N2) or ambient room air for various times (n = 4–6 per condition). In some experiments, mice were administered either recombinant human ITF (30 mg/kg, 75% gastric lavage, 25% enema) or PBS 1 h before hypoxia. Cardiach blood was performed and serum analysis of FITC concentration performed. In subsets of experiments, tissues were collected from wild-type and ITF null mice after hypoxia and fixed in 10% buffered formalin. 5-μm sections were cut, stained with hematoxylin and eosin, and histologically characterized. Colonic tissue was harvested and homogenized and RNA extracted with Trizol as described above. Another section of colonic mucosal scrapings was harvested and processed for Western blot analysis as described above. This protocol was in accordance with National Institutes of Health guidelines for use of live animals and was approved by the Institutional Animal Care and Use Committee at Brigham and Women’s Hospital.
Statistical Analyses. ITF bioactivity and paracellular permeability data were compared by one- or two-factor analysis of variance or by Student’s t test where appropriate. Values are expressed as the mean and SEM from at least three separate experiments.

Results

Colonic Epithelia Resist Hypoxia-elicited Barrier Changes. Previous reports indicate that colonic epithelial barrier function is maintained during even severe conditions of hypoxia (13, 14). In contrast, other cell types (e.g., vascular endothelia) appear to markedly lose barrier qualities during ambient hypoxia (23). As shown in Table I, comparison of six barrier cell types revealed that colonic epithelial cells (T84 and Caco-2 cells), as opposed to other epithelia (KB, A549, and MDCK) or MVECs, appear to be uniquely resistant to increased permeability induced by hypoxia, suggesting that intestinal epithelial cells possess mechanisms that sustain barrier function under such conditions.

Hypoxia Induces ITF Production. Transcriptional profiling has been used to identify potential factors contributing to maintenance of barrier during hypoxia (24, 25). Microarray analysis (26) was adopted to broadly screen hypoxia-regulated genes in RNA derived from intestinal epithelia (T84 cells), and identified a time-dependent induction of the intestinal-specific, barrier-protective ITF gene (2.8- and 4.2-fold increase over control normoxia at 6- and 18-h hypoxia, respectively). Subsequently, RT-PCR analysis was employed to corroborate results of microarray screening (Fig. 1 a). This analysis of Caco-2 cells demonstrated a time-dependent induction of ITF mRNA expression, and was evident by 4-h exposure to hypoxia. Similar results were seen in T84 cells (data not shown). Epithelial exposure to the RNA synthesis inhibitor actinomycin D blocked this hypoxia-elicited ITF induction (Fig. 1 b), indicating that this response reflects new transcriptional activity.

Table I. Intestinal Epithelia Resist Hypoxia-elicited Disruption

| Cell type          | Paracellular flux |          |          |          |          |
|--------------------|-------------------|----------|----------|----------|----------|
|                    | Normoxia          | Hypoxia  | Fold increase | P value |          |
|                    | pM/cm²/h          | pM/cm²/h |          |          |          |
| Epithelia (T84, colon) | 5 ± 0.4           | 5 ± 0.3  | 0.0      | NS       |          |
| Epithelia (Caco-2, colon) | 8 ± 1.6           | 9 ± 0.8  | 0.1      | NS       |          |
| Epithelia (KB, oral)   | 97 ± 8.1          | 430 ± 12.6 | 4.4 | <0.001  |          |
| Epithelia (MDCK, kidney) | 63 ± 10.4        | 245 ± 12.2 | 3.8 | <0.001  |          |
| Epithelia (A549, lung) | 197 ± 19.5        | 482 ± 52.5 | 2.4 | <0.007  |          |
| Epithelia (MVEC, dermis) | 127 ± 5.1         | 395 ± 14.6 | 3.1 | <0.001  |          |

Monolayers of indicated cell type were grown to confluence on semipermeable supports. Monolayers were exposed to normoxia (pO₂ = 147 Torr) or hypoxia (pO₂ = Torr) for 24 h (48 for A549 cells) at 37°C. Paracellular permeability of fluoresceinated dextran (40 kD, 70 kD for A549 cells) was assessed over a 60-min period and flux was calculated from a standard curve. Results represent mean and SEM from at least three separate experiments.

Figure 1. ITF induction of hypoxia. Confluent Caco-2 epithelial monolayers were exposed to indicated periods of ambient hypoxia (pO₂ = 20 Torr) or normoxia (pO₂ = 147 Torr). In a, total RNA was isolated and examined for ITF transcript by RT-PCR. β-Actin transcript was used as an internal control. In b, Caco-2 cells were pretreated with vehicle or actinomycin D (Act. D) before 24 h of hypoxia or normoxia. Total RNA was isolated and examined for ITF mRNA. In c, soluble supernatants derived from monolayers exposed to indicated periods of hypoxia were examined for ITF content by SDS-PAGE and Western blot analysis.
confirm these mRNA observations at the protein level, Western blot analysis of soluble supernatants confirmed an increase of secreted ITF protein by 48 h (Fig. 1 b).

**ITF Production Is HIF-1 Dependent.** Prompted by these results, a search of the cloned ITF gene identified a previously unappreciated HIF-1α binding site at positions −129 to −122 relative to the transcription start site (17) (DNA consensus motif 5′-TACGTGGG-3′; reference 6). Consequently, we assessed the induction of HIF-1α and ITF by hypoxia. First, we determined whether conditions of hypoxia induce HIF-1α in intestinal epithelia (Fig. 2 a). Western blot analysis of nuclear lysates derived from hypoxic intestinal epithelia Caco-2 cells demonstrated abundant HIF-1α in nuclei. These data are consistent with previous studies suggesting that HIF-1α is expressed in most cell types during periods of hypoxia (3). Next, we examined the binding of HIF-1α to the HRE consensus in the ITF promoter by EMSA (Fig. 2 b). As can be seen, nuclear extracts derived from hypoxic, but not normoxic, Caco-2 cells bind to the HIF-1α consensus of the ITF promoter. Pretreatment of epithelia with 100 μM CoCl2 for 4 h, conditions that promote nuclear accumulation of HIF-1α (5), resulted in a similar band shift. Addition of anti–HIF-1α mAb, but not isotype-matched mAb, resulted in a diminution of shifted signal, but no obvious supershift consistent with Ab interference with DNA–protein interaction. Incubation with 100-fold excess unlabeled primer resulted in complete loss of signal. Collectively, these results indicate that hypoxia elicits nuclear accumulation of HIF-1α, which binds to the consensus HRE located within the ITF promoter.

As proof of principle for this concept, intestinal epithelial cell lines overexpressing HIF-1α were generated by stable transfection (Fig. 3 a). As shown in Fig. 3 b, overexpression of HIF-1α resulted in increased basal expression of ITF and enhanced hypoxia-elicited induction of ITF. Next, antisense oligonucleotides directed against HIF-1α were used to block HIF-1α expression (Fig. 3 c) and the influence of HIF-1α depletion on ITF mRNA induction by hypoxia was assessed (Fig. 3 d). As can be seen, the directed loss of HIF-1α resulted in a nearly complete loss of ITF mRNA expression at 4- and 24-h periods of hypoxia. Control oligo.
gonucleotides generated to the sense strand of HIF-1α did not influence ITF hypoxia inducibility. Taken together, these results indicate that hypoxia induces a time-dependent HIF-1α nuclear accumulation and parallel ITF induction.

**ITF Promotes Barrier Function In Vitro and In Vivo.** Given the findings described above, studies were undertaken to determine whether ITF played a functional role in maintenance of the epithelial integrity during hypoxia. For this purpose, Caco-2 monolayers were exposed to hypoxia in the presence or absence of anti-ITF (Fig. 4 a). Increasing concentrations of anti-ITF sera (titer ~1:100,000), but not isotype-matched antisera, resulted in a dose-dependent increase in epithelial permeability in response to hypoxia (no Ab versus anti-human [h] ITF at 1:100 dilution; \( P < 0.001 \)). These results demonstrate that ITF participates in the maintenance of barrier function during hypoxia. Further evidence in support of ITF as a barrier-protective agent was provided by addition of recombinant hITF to hypoxia-sensitive cells. Monolayers of endothelial cells (which respond to hypoxia with increase paracellular permeability, Table I) were used to define this principle. As shown in Fig. 4 b, addition of hITF to confluent endothelial cells during conditions of hypoxia resulted in a concentration-dependent protection against barrier disruption (no hITF versus 1 mg/ml hITF, \( P < 0.01 \)). These data provide direct evidence for a key role of ITF protein in barrier protection and suggest that ITF’s functional action may be independent of the cell type, as illustrated here by the vascular endothelia.

To define the role of hypoxia-elicited ITF on mucosal barrier in vivo, intestinal permeability was examined in wild-type and ITF null mice (21) during 4-h exposure to ambient hypoxia (8% \( \text{O}_2 \)). Under such conditions, increases in both ITF mRNA (Fig. 5 a) and protein (Fig. 5 b) were induced in tissues derived from wild-type animals subjected to hypoxia. As shown in Fig. 5 c, upon exposure to hypoxia, ITF null mice exhibited a significantly greater increase in intestinal permeability to FITC-dextran (4 kD) when compared with wild-type mice (ITF knockout versus wild-type exposed to hypoxia; \( P < 0.01 \)). Interestingly, no histologically evident lesions were observed in the colonic mucosa with 4-h exposure to hypoxia (representative section from wild-type and ITF null animals are shown in Fig. 5 d). Longer periods of time in hypoxia did not significantly increase intestinal permeability beyond the 4-h time point. For example, intestinal permeability of wild-type animals subjected to hypoxia for 18 h (3.3 ± 1.2-fold increase in permeability, \( n = 4 \) animals) were not different than animals exposed to 4-h hypoxia (4.4 ± 1.3-fold increase, \( n = 19 \) animals). Moreover, these longer time periods resulted in an unexpected death in ITF null (four out of six animals tested) but not wild-type animals (zero out of six animals tested, data not shown). Interestingly, increased intestinal permeability was also evident in ITF null mice not exposed to hypoxia as compared with wild-type (\( P < 0.05 \) for ITF null compared with wild-type exposed to normoxia), consistent with the presumption that ITF may contribute to the maintenance of intestinal barrier under physiological conditions.

To further define these principles, wild-type and ITF null mice were administered recombinant ITF protein (30 mg/kg in PBS with 75% intragastric and 25% rectal infusion) before hypoxia. These studies revealed that administration of ITF to normoxic ITF null animals resulted in a significant decrease in permeability (550 ± 40 vs. 320 ± 90 ng/ml in the absence and presence of ITF administration, respectively; \( n = 4 \) mice per condition, \( P < 0.04 \)). ITF added-back to ITF null mice in hypoxia resulted in a trend toward resolution of increased permeability (1,310 ± 310 and 970 ± 110 ng/ml in the absence and presence of ITF administration; \( n = 6 \) mice per condition), however, these results were not statistically significant (\( P > 0.05 \)). Similar to these results, ITF administration to wild-type mice in nor-
Hypoxia-inducible Factor 1–dependent Induction of Intestinal Trefoil Factor

moxia and hypoxia trended toward resolution of increased permeability but were not statistically significant (data not shown).

**Discussion**

These studies provide the first molecular link between hypoxia and intestinal epithelial barrier protection. Here, we identify a previously unappreciated HIF-1α regulated pathway for induction of ITF. ITF is a small, protease-resistant peptide that is abundant throughout the mammalian intestinal tract (27, 28). Increased ITF expression has been observed in proximity to sites of injury in the gastrointestinal tract, including peptic ulcers and active inflammatory bowel disease (27–29). ITF can promote epithelial barrier function, protecting against injury, and facilitating repair after damage occurs irrespective of the nature of the initial wound. However, specific transcriptional pathways for ITF induction are not well understood (30).

The hypoxia-dependent production of ITF represents a novel, innate protective mechanism that may guard the immunologic components of the lamina propria from exposure to pathogenic luminal bacteria, antigens, and toxins during episodes of diminished oxygen delivery. Accumulating evidence suggests a variety of physiological roles for ITF (28), however, molecular mechanisms regulating ITF expression have not been studied in detail. Rather, the signaling pathways activated by the addition of exogenous ITF have been more closely examined and include the activation of extracellular signal regulatory kinase, regulated expression of α- and β-catenin, and transactivation of the epidermal growth factor receptor (31–33). Recent work has delineated that ITF can elicit distinct signaling pathways for epithelial restitution and inhibition of apoptosis, the latter of which involves activation of mitogen-activated protein kinase pathways independent of epidermal growth factor receptor phosphorylation (33). Important for the present studies, these same extracellular signal regulatory kinase pathways were recently demonstrated to critically function in the development of intestinal epithelial barrier function through regulated expression of claudin-2 and organization of membrane proteins within the tight junction (34). Thus, it is likely that ITF-specific, extracellular signaling pathways regulate epithelial barrier under these defined conditions.

At the tissue and cellular level, an array of genes pivotal to survival in low oxygen states are activated (4, 35–37). Original studies of hypoxia-induced EPO production concentrated on the regulation of gene transcription. Sequences from the EPO promoter were isolated and identified as a heterodimer with independently regulated subunits termed HIF-1, a member of the rapidly growing per-ARNT-sim family of basic helix-loop-helix transcription factors (5, 6). HIF-1 exists as an αβ heterodimer, the activation of which is dependent on stabilization of an O2-dependent degradation domain of the α subunit by the ubiquitin–proteasome pathway (7). Although not certain, HIF-1 appears to reside in the cytoplasm of normoxic cells, and like a number of other transcription factors (e.g., nuclear factor κB, β-catenin), HIF-1 translocates to the nucleus to form a functional complex (38, 39). Binding of HIF-1 to consensus domains in the EPO enhancer results in the transcriptional induction of HIF-1–bearing gene promoters (4). Subsequently, it was determined that HIF-1 is widely expressed and that consensus HIF-1–binding sequences exist in a number of genes other than EPO and are termed HRE (4). Of note on this accord, we did not precisely map the ITF HRE. Attempts to define this site in exac terms were hampered by the complexity of the flanking region around the HIF-1 consensus sequence (data not shown). For example, the immediate region of the HIF-1 consensus site also contains consensus binding sites for the transcription factors myeloid zinc finger–1 (MZF1, consensus 5′-AGGGGA-3′), GATA-1 (consensus 5′-GGG-GATTCTG-3′), GATA-2 (consensus 5′-CAGGA-TAAGG-3′), Sp1 (consensus 5′-GTGGCAGGGT-3′), MyoD (consensus 5′-GCTGTCCACCGG-5′), and upstream stimulatory factor (USF, consensus 5′-CCAC-
CTGT-3'). Important in this regard, at least three of these transcription factors (GATA-1, GATA-2, and MyoD) have been recently implicated in either induction or repression of genes in hypoxia (40–43). Therefore, it is possible that regulation of the ITF gene at this site could be an interplay of positive and negative signaling pathways, and given this complexity, more work will be necessary to define the exact details of this HRE.

Our results suggest that ITF may represent a potential novel therapeutic approach for a variety of diseases associated with mucosal hypoxia and altered epithelial barrier function, including inflammatory bowel disease, necrotizing enterocolitis, and ischemic colitis (44). In addition, these results suggest that a receptor/binding site for ITF may be present at sites other than the gastrointestinal tract, such as the endothelium. Thus, the protective effect of ITF on the hypoxia-induced decline in endothelial permeability suggests that ITF may have ever broader therapeutic relevance in conditions of vascular leakiness such as septic shock. Although it is unknown whether ITF would function alone in these responses, it is possible, as previously proposed, that ITF acts in concert with and complementary to other protective growth factors and cytokines resident at sites of tissue damage (29). Efforts to better understand ITF signaling pathways and to identify other hypoxia-elicited protective elements could provide future focus for the development of novel treatments.

We thank Eric Black, Kristin Synnestvedt, and Robyn Carey for their superb technical assistance. The authors also thank I.K. Ezedi and I. Rosenberg for production of recombinant ITF used in these studies.

This work was supported by National Institutes of Health grants DK02564 (to G.T. Furuta), DK02682 (to C.T. Taylor), DK02503 (to J. Turner), DK43351 and DK46776 (to D.K. Podolsky), and DK50189 and HL60569 (to S.P. Colgan).

Submitted: 18 July 2000
Revised: 8 February 2001
Accepted: 26 March 2001

References
1. Madara, J.L. 1998. Regulation of the movement of solutes across tight junctions. Annu. Rev. Physiol. 60:143–159.
2. Taylor, C.T., and S.P. Colgan. 1999. Therapeutic targets for hypoxia-elicited pathways. Pharmacol. Res. 16:1498–1505.
3. Semenza, G.L. 1999. Perspectives on oxygen sensing. Cell. 98:281–284.
4. Semenza, G.L. 1998. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr. Opin. Genet. Dev. 8:588–594.
5. Wang, G.L., and G.L. Semenza. 1995. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270: 1230–1237.
6. Wang, G.L., B.H. Jiang, E.A. Rue, and G.L. Semenza. 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular oxygen tension. Proc. Natl. Acad. Sci. USA. 92:5510–5514.
7. Huang, L.E., J. Gu, M. Schau, and H.F. Bunn. 1998. Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA. 95:7987–7992.
8. Turner, J.R., W.I. Lencer, S. Carlson, and J.L. Madara. 1996. Carboxy-terminal vesicular stomatitis virus G protein-tagged intestinal Na⁺-dependent glucose cotransporter (SGLT1): maintenance of surface expression and global transport function with selective perturbation of transport kinetics and polarized expression. J. Biol. Chem. 271:7738–7744.
9. Madara, J.L., J. Stafford, K. Dharmasathaphorn, and S. Carlson. 1987. Structural analysis of a human intestinal epithelial cell line. Gastroenterology. 92:1133–1145.
10. Eagle, H. 1958. Propagation in a fluid medium of a human epidermoid carcinoma, strain KB. Proc. Soc. Exp. Biol. Med. 94:362–364.
11. Lennon, P.F., C.T. Taylor, G.L. Stahl, and S.P. Colgan. 1998. Neutrophil-derived 5′-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J. Exp. Med. 188:1433–1443.
12. Sambuy, Y., and E. Rodriguez-Boulan. 1988. Isolation and characterization of the apical surface of polarized Madin-Darby canine kidney epithelial cells. Proc. Natl. Acad. Sci. USA. 85:1529–1533.
13. Colgan, S.P., A.L. Dzus, and C.A. Parkos. 1996. Epithelial exposure to hypoxia modulates neutrophil transepithelial migration. J. Exp. Med. 184:1003–1013.
14. Taylor, C.T., N. Fueki, A. Agah, R.M. Hershberg, and S.P. Colgan. 1999. Critical role of cAMP response element binding protein expression in hypoxia-elicited induction of epidermal TNFα. J. Biol. Chem. 274:19447–19450.
15. Zünd, G., D.P. Nelson, E.J. Neufeld, A.L. Dzus, J. Bischof, J.E. Mayer, and S.P. Colgan. 1996. Hypoxia enhances stimulus-dependent induction of E-selectin on aortic endothelial cells. Proc. Natl. Acad. Sci. USA. 93:7075–7080.
16. Lockhart, D.J., H. Dong, M.C. Byrne, M.T. Follettie, M.V. Gallo, M.S. Chee, M. Mittmann, C. Wang, M. Kobayashi, H. Horton, and E.L. Brown. 1996. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat. Biotechnol. 14:1675–1680.
17. Seib, T., S. Dooley, and C. Welter. 1995. Characterization of the genomic structure and the promoter region of the human intestinal trefoil factor. Biochem. Biophys. Res. Commun. 214:195–199.
18. Zünd, G., S. Uezono, G.L. Stahl, A.L. Dzus, F.X. McGowan, P.R. Hickey, and S.P. Colgan. 1997. Hypoxia enhances endotoxin-stimulated induction of functional intercellular adhesion molecule-1 (ICAM-1). Am. J. Physiol. 273: C1571–C1580.
19. Ogata, H., and D.K. Podolsky. 1997. Trefoil peptide expression and secretion is regulated by neuropeptides and acetylcholine. Am. J. Physiol. 273:G348–G354.
20. Caniggia, I., H. Mostachfi, J. Winter, M. Gassmann, S.J. Lye, M. Kuliszewski, and M. Post. 2000. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFβ(3). J. Clin. Invest. 105:577–587.
21. Mashimo, H., D.C. Wu, D.K. Podolsky, and M.C. Fishman. 1996. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science. 274:262–265.
22. Napolitano, L.M., M.J. Koruda, A.A. Meyer, and C.C. Baker. 1996. The impact of femur fracture with associated soft tissue injury on immune function and intestinal permeability. Shock. 5:202–207.
Braunstein, C. Butura, J. Brett, H.B. Leiberman, M.B. Furie, J. Joseph-Silverstien, and D. Stern. 1991. Macrovacular and microvascular endothelium during long-term hypoxia: alterations in cell growth, monolayer permeability, and cell surface coagulant properties. *J. Cell. Physiol.* 146:8–17.

24. Furuta, G.T., A.L. Dzus, C.T. Taylor, and S.P. Colgan. 2000. Parallel induction of epithelial surface-associated chemokine and proteoglycan by cellular hypoxia: implications for neutrophil activation. *J. Leukoc. Biol.* 68:251–259.

25. Taylor, C.T., G.T. Furuta, K. Synnestvedt, and S.P. Colgan. 2000. Phosphorylation-dependent targeting of cAMP response element binding protein to the ubiquitin/proteasome pathway in hypoxia. *Proc. Natl. Acad. Sci. USA.* 97:12091–12096.

26. Zweiger, G. 1999. Knowledge discovery in gene-expression-microarray data: mining the information output of the genome. *Trends Biotechnol.* 17:429–436.

27. Thim, L. 1997. Trefoil peptides: from structure to function. *Cell. Mol. Life Sci.* 53:888–903.

28. Giraud, A.S. 2000. X. Trefoil peptide and EGF receptor/ligand transgenic mice. *Am. J. Physiol. Gastrointest. Liver Physiol.* 278:G501–G506.

29. Beck, P.L., and D.K. Podolsky. 1999. Growth factors in inflammatory bowel disease. *Inflamm. Bowel Dis.* 5:44–60.

30. Ogata, H., N. Inoue, and D.K. Podolsky. 1998. Identification of a goblet cell-specific enhancer element in the rat intestinal trefoil factor gene promoter bound by a goblet cell nuclear protein. *J. Biol. Chem.* 273:3060–3067.

31. Efstathiou, J.A., M. Noda, A. Rowan, C. Dixon, R. Chinery, A. Jawhari, T. Hattori, N.A. Wright, W.F. Bodner, and M. Pignatelli. 1998. Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. *Proc. Natl. Acad. Sci. USA.* 95:3122–3127.

32. Kanai, M., C. Mullen, and D.K. Podolsky. 1998. Intestinal trefoil factor induces inactivation of extracellular signal-regulated protein kinase in intestinal epithelial cells. *Proc. Natl. Acad. Sci. USA.* 95:178–182.

33. Kinoshita, K., D.R. Taupin, H. Itoh, and D.K. Podolsky. 2000. Distinct pathways of cell migration and antiapoptotic response to epithelial injury: structure-function analysis of human intestinal trefoil factor. *Mol. Cell. Biol.* 20:4680–4690.

34. Kinugasa, T., T. Sakaguchi, X. Gu, and H.C. Reinecker. 2000. Claudins regulate the intestinal barrier in response to immune mediators. *Gastroenterology.* 118:1001–1011.

35. Bunn, H.F., and R.O. Poyton. 1996. Oxygen sensing and molecular adaptation to hypoxia. *Physiol. Rev.* 76:839–885.

36. Gassmann, M., and R.H. Wenger. 1997. HIF-1, a mediator of the molecular response to hypoxia. *Neus Physiol. Sci.* 21:218–218.

37. Ratcliffe, P.J., J.F. O’Rourke, P.H. Maxwell, and C.W. Pugh. 1998. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. *J. Exp. Biol.* 201:1153–1162.

38. Presta, L.G., H. Chen, S.J. O’Conner, V. Chisholm, Y.G. Meng, L. Krummen, M. Winkler, and N. Ferrara. 1997. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. *Cancer Res.* 57:4593–4599.

39. Kallio, P.J., W.J. Wilson, S. O’Brien, Y. Makino, and L. Poellinger. 1999. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. *J. Biol. Chem.* 274:6519–6525.

40. Minet, E., D. Mottet, G. Michel, I. Roland, M. Raes, J. Remacle, and C. Michiels. 1999. Hypoxia-induced activation of HIF-1: role of HIF-1α-Hsp90 interaction. *FEBS Lett.* 460:251–256.

41. De Maria, R., A. Zeuner, A. Eramo, C. Domenichelli, D. Bonci, F. Grignani, S.M. Strinivasula, E.S. Alnemri, U. Testa, and C. Peschle. 1999. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. *Nature.* 401:489–493.

42. Kramer, M.F., P. Gunaratne, and G.C. Ferreira. 2000. Transcriptional regulation of the murine erythroid-specific 5-aminolevulinate synthase gene. *Gene.* 247:153–166.

43. Taramoto, T., S. Imagawa, K. Ohmine, T. Nagai, M. Higuchi, N. Imai, N. Suzuki, M. Yamamoto, and K. Ozawa. 2000. N(G)-monomethyl-L-arginine inhibits erythropoietin gene expression by stimulating GATA-2. *Blood.* 96:1716–1722.

44. Unno, N., and M.P. Fink. 1998. Intestinal epithelial hyperpermeability. Mechanisms and relevance to disease. *Gastroenterol. Clin. North Am.* 27:289–307.